Cargando…
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
We conducted a phase I study in ovarian cancer patients to evaluate the safety and immunogenicity of a synthetic unimolecular pentavalent carbohydrate vaccine (Globo-H, GM2, sTn, TF, and Tn) supported on a peptide backbone, conjugated to keyhole limpet haemocyanin (KLH), and mixed with immunological...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846855/ https://www.ncbi.nlm.nih.gov/pubmed/27110823 http://dx.doi.org/10.3390/cancers8040046 |
_version_ | 1782429115611086848 |
---|---|
author | O’Cearbhaill, Roisin E. Ragupathi, Govind Zhu, Jianglong Wan, Qian Mironov, Svetlana Yang, Guangbin Spassova, Maria K. Iasonos, Alexia Kravetz, Sara Ouerfelli, Ouathek Spriggs, David R. Danishefsky, Samuel J. Sabbatini, Paul J. |
author_facet | O’Cearbhaill, Roisin E. Ragupathi, Govind Zhu, Jianglong Wan, Qian Mironov, Svetlana Yang, Guangbin Spassova, Maria K. Iasonos, Alexia Kravetz, Sara Ouerfelli, Ouathek Spriggs, David R. Danishefsky, Samuel J. Sabbatini, Paul J. |
author_sort | O’Cearbhaill, Roisin E. |
collection | PubMed |
description | We conducted a phase I study in ovarian cancer patients to evaluate the safety and immunogenicity of a synthetic unimolecular pentavalent carbohydrate vaccine (Globo-H, GM2, sTn, TF, and Tn) supported on a peptide backbone, conjugated to keyhole limpet haemocyanin (KLH), and mixed with immunological adjuvant QS-21. Twenty-four advanced-stage, poor-risk, first-remission ovarian cancer patients were enrolled from January 2011–Septermber 2013. Three dose levels were planned (25, 50, 100 mcg) with three cohorts of six patients each, with an additional 6-patient expansion cohort at the MTD. ELISA serologic IgM and IgG responses for each antigen was defined as positive response if antibody titers were ≥1:80 over the respective patient’s pre-vaccination serum. The study would be considered positive if at least four of 12 patients treated at the MTD showed immune responses for at least three of the five antigens. Twenty-four patients (median age, 54 years [range, 36–68]) were included in the safety analysis. Histology was high-grade serous in 22 patients (92%); 18 had stage III and six stage IV disease. The vaccine was well-tolerated at all doses, with no DLTs. At the highest treated dose, IgG and/or IgM responses were recorded against ≥3 antigens in 9/12 patients (75%), ≥4 in 7/12 (58%), and 5 in 3/12 (25%). With a median follow-up of 19 months (range, 2–39), 20 patients (83%) recurred and six (25%) died. The unimolecular pentavalent vaccine construct was shown to be safe and immunogenic. Such a construct greatly simplifies regulatory requirements and manufacturing, facilitates scalability, and provides adaptability. |
format | Online Article Text |
id | pubmed-4846855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-48468552016-05-04 A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission O’Cearbhaill, Roisin E. Ragupathi, Govind Zhu, Jianglong Wan, Qian Mironov, Svetlana Yang, Guangbin Spassova, Maria K. Iasonos, Alexia Kravetz, Sara Ouerfelli, Ouathek Spriggs, David R. Danishefsky, Samuel J. Sabbatini, Paul J. Cancers (Basel) Article We conducted a phase I study in ovarian cancer patients to evaluate the safety and immunogenicity of a synthetic unimolecular pentavalent carbohydrate vaccine (Globo-H, GM2, sTn, TF, and Tn) supported on a peptide backbone, conjugated to keyhole limpet haemocyanin (KLH), and mixed with immunological adjuvant QS-21. Twenty-four advanced-stage, poor-risk, first-remission ovarian cancer patients were enrolled from January 2011–Septermber 2013. Three dose levels were planned (25, 50, 100 mcg) with three cohorts of six patients each, with an additional 6-patient expansion cohort at the MTD. ELISA serologic IgM and IgG responses for each antigen was defined as positive response if antibody titers were ≥1:80 over the respective patient’s pre-vaccination serum. The study would be considered positive if at least four of 12 patients treated at the MTD showed immune responses for at least three of the five antigens. Twenty-four patients (median age, 54 years [range, 36–68]) were included in the safety analysis. Histology was high-grade serous in 22 patients (92%); 18 had stage III and six stage IV disease. The vaccine was well-tolerated at all doses, with no DLTs. At the highest treated dose, IgG and/or IgM responses were recorded against ≥3 antigens in 9/12 patients (75%), ≥4 in 7/12 (58%), and 5 in 3/12 (25%). With a median follow-up of 19 months (range, 2–39), 20 patients (83%) recurred and six (25%) died. The unimolecular pentavalent vaccine construct was shown to be safe and immunogenic. Such a construct greatly simplifies regulatory requirements and manufacturing, facilitates scalability, and provides adaptability. MDPI 2016-04-22 /pmc/articles/PMC4846855/ /pubmed/27110823 http://dx.doi.org/10.3390/cancers8040046 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article O’Cearbhaill, Roisin E. Ragupathi, Govind Zhu, Jianglong Wan, Qian Mironov, Svetlana Yang, Guangbin Spassova, Maria K. Iasonos, Alexia Kravetz, Sara Ouerfelli, Ouathek Spriggs, David R. Danishefsky, Samuel J. Sabbatini, Paul J. A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission |
title | A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission |
title_full | A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission |
title_fullStr | A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission |
title_full_unstemmed | A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission |
title_short | A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission |
title_sort | phase i study of unimolecular pentavalent (globo-h-gm2-stn-tf-tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846855/ https://www.ncbi.nlm.nih.gov/pubmed/27110823 http://dx.doi.org/10.3390/cancers8040046 |
work_keys_str_mv | AT ocearbhaillroisine aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT ragupathigovind aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT zhujianglong aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT wanqian aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT mironovsvetlana aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT yangguangbin aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT spassovamariak aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT iasonosalexia aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT kravetzsara aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT ouerfelliouathek aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT spriggsdavidr aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT danishefskysamuelj aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT sabbatinipaulj aphaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT ocearbhaillroisine phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT ragupathigovind phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT zhujianglong phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT wanqian phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT mironovsvetlana phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT yangguangbin phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT spassovamariak phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT iasonosalexia phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT kravetzsara phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT ouerfelliouathek phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT spriggsdavidr phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT danishefskysamuelj phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission AT sabbatinipaulj phaseistudyofunimolecularpentavalentglobohgm2stntftnimmunizationofpatientswithepithelialovarianfallopiantubeorperitonealcancerinfirstremission |